INKT - Earnings call 3 2023 | MiNK Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to MiNK Therapeutics Third Quarter 2023 Conference Call and Webcast. All participants will be in a listen-only mode until the question-and-answer session. Please note this event is being recorded. If anyone has any objections, you may now disconnect at this time.I will now turn the call over to Zack Armen, Head of Investor Relations at MiNK.

Zack Armen

Thank you, operator, and thank you all for joining us today. webcasted be being website on is replay. for call and available will our Today's remind this regulatory you forward-looking to opportunities. lines like I'd that and release statements as as partnership our for plans data statements, call regarding clinical commercial development, and well time including contain will These the more we these details you statements risks.Joining risks call our to me and subject uncertainties, to on are on Dr. SEC are today and refer filings for Chief Jennifer Officer; Executive Buell, and President Dr. Officer; Scientific Officer. Chief Marcus Christine Klaskin, Accounting Dijk, van and Financial and Principal

progress Now over I'd year like to Dr. to XXXX turn the Buell call to and highlight in the for plans ahead. our

Jennifer Buell

or cells bit lymphodepletion benefits particularly a related iNKTs, that without shortly. for of SITC preconditioning. Thank testament quarter and of excellent progress distinguished to made is and robust presenting tell this data, of unique persistence preconditioning you, properties scalability, AgenT-XXX therapy, the all third pipeline recent the findings was being earnings its Society cells.The SITC these you flagship call proprietary place toxic these to reiterate, first-of-kind compelling XXX have new or a lengthy of of quarter, meeting about of A particularly XXXX. need headway we've an Immunotherapy with to administration included it's pleasure the product, cell pinnacle Zack. by the many on our It's our regimen, last the immunomodulatory technology week. I'm at to annual versatility without highlighting on promise allogeneic MiNK's Marcus more programs. with us for To iNKT the that you cell iNKT took its toxic and for can at this reported excited data a report Cancer

of prior solid long-term late-stage cancer, treatment XX% non-small durable observed cancer reported in treated. to like exhausted durable an Notably, to durable prior in more than in observed used patients chemotherapy potential types of to patients these a with therapy. is we a biomarker AgenT-XXX and prior commonly lung evidence unresponsive prior as that an continued from continued across holds appendiceal we clinical metastatic data diverse and options. with combined well metastatic as immune So continued. was prior exciting testicular that with have the all refractory and the on anti-PD-X therapies finding cell for chemo anti-PD-X.Additionally, were other refractory tumor benefit patients responses provide This tumor the update are cancers. and/or of patients with cancer disease responses chemo, set AgenT-XXX cancers second-line in Friday, This stabilization gastric These cancer last the patient chemotherapy in therapy, who patient us,

cells cancer, Our data presentations of benefit also iNKT in including underscore infections, and beyond inflammatory diseases the autoimmunity.

that range in Just we were the earlier presented of half patients on is blood externally program in-hospital XX% where a to promote of data, year earlier to oxygenated well form are compared to point.We support, billion survival these earlier That's the widely time exceeding as of ventilation XX% the this along being viral reported life alone with And externally. with severe patients ECMO with used financed therapy, their same on in also we include others these a of tolerated survival to VV ventilation. patients at rates. who as this step And controls XX% patients tumor have through the anywhere XX% most continue agenT-XXX up mechanical XX% data well to compared at International an expand X end Meeting, showed than ARDS the benefit controls cells These is May, more from platforms. agenT-XXX Meeting, of and most solid also when immune on with in improved some presented cancers. cells showed mechanical that plans demonstrate ranges survival to combination XX% at Thoracic that continue American and treated a Lung this in AACR to in-hospital of clinical Society we year, the

we've Another from persistence. finding new and translational insights these are the important data their mechanisms their into long-term immune iNKT cells, that generated modulating

today.I'm to XXX's has responses immune Our and discuss infiltration been our ability other what observed Dijk, cell data accelerate turn demonstrated discoveries. amplify call with these about Marcus van the over more beyond Chief promote Officer at to tumor therapy that MiNK to going and to any Dr. persist, Scientific

Marcus van Dijk

Thank you, Jen.

our As do clinic, to can for of we're use encouraged cancer, with cells more by with other in more and the the unique potential iNKT of what or they patients understanding deepen agents. continue we alone mechanisms combination in the

showed we We spikes and This cytokine of changes immune cancer activation active durable as within in patients spike So dose. of of iNKT combination retain trial in iNKT of an levels gamma, data first-of-a-kind our the require respect, activation interferon and and activity immune state the combining iNKT the escaping an tumors locally systemic system hours post-infusion therapy clearest system systemically in have remain signatures enhanced back clear responses that immune when immune going these to with And the to high such elevated elevated upon important interferon system infusion trial. The key vigilant. In of the potentially One show we agenT-XXX.The cancer. the in tumor, in hallmark serum activation this patients persistence vigilant levels. immune from patient's finding immune both demonstrate immune is system allogeneic indicating persistent. needs tumor that treated with the that blood interferon the the gamma activation. indicative a is as to interferon potentially patients, prevent agenT-XXX.Now in interferon see anti-PD-X all it's infusion control correlates changes is well patients gamma activating of are in of anticancer of baseline post slightly in in spike of tumor of activation anti-PD-X a signal and of our of interestingly, observed XX agenT-XXX cancer system treated A patient's the gamma. gamma and of patient's blood And is signals again. in key the cell with

duplex we method very SNP on by based Here a specific used blood analysis mononuclear of independent cells. high-sensitivity peripheral donor-specific sequencing

showing stable response at disease. blood They patients in persistence, with persists appear So we levels least long response. of And addition to such for also found in saw correlate we to that that higher in agenT-XXX months. is X patients and with partial agenT-XXX

of stay used allogeneic to months is in is cell remarkable. knowledge therapies what with the an the of between around cell it for remarkable HLA has today.Even higher the the is matching. toxic the and product stay pretreatment administered when for tissue independent X donor be that donor more matching Traditional tolerated clinical Even use tissue a majority we apparently that degree and are was HLA for which agenT-XXX longer will functional. for ideally persistence patient, so finding of So patient, is the more

cells in for Over nature great cancer to disorders. of natural underpins further responding immune-mediated even when unique X for in potential for iNKT in months least the allogeneic XX was that out our of support patients finding T the there killer use invariant and only cancer X therapy you, to gastric match, cells other Our persist HLA at Jen. provides and

Jennifer Buell

a iNKT theoretical thank of as the actually observations you. team's is available set quite and cells findings are observing advantages fruition than This types dedication well comes clinical in witnessing, observed really with our practice to testament of work other Appreciate and overview, innovation. is true as unique to what translational Marc, your data in Marc. profound cell that and we different the

on it's attention scientific underpins prudence to acknowledge also journey. As that our it reflect advancements, we important our and financial truly really our

with those continued earlier well. our insights the clinical is outflow, findings launched off-the-shelf at discipline with which The scale internalization and presented long-term it's pronounced iNKT were this cash progress respiratory and iNKT durable correlating that alone a carefully presented we've contained cells with to managed We and pembrolizumab. therapy with different programs clinical data with acute and patients support the SITC, we demonstrated programs. presented.And X this also a as done virally and Marc trial benefit approved manufacturing by in X observations anti-PD-X induced nivolumab just data Our launched we've We been up. at process at of allogeneic AACR of those and combination in recently our And most last also these co of clinical completion cells commercially flow the conferences. of year most year studied but now translational in cash cells and distress our

burn rate, cash in ahead, FDA that made beyond progress of And process an is donor of have and automated, X,XXX external to doses that anticipate cleared a and ability reduction now now internalized, be we the meaningful clinical per our scalable, our per [ the quarterly manufacturing programs. in fully ]. highly X,XXX doses Looking by beyond year our has closed included importantly, will we've financing

to development to for has we're advancing been our programs have us, we So going critical and different clinical ways. support the do process few in continuing the a so now needs importantly, forward.Now

the the chemotherapy of severe of as this And stem settings standard iNKTs we balstilimab, designed Center trials combination only our build Chief gastric have mitigate are exciting specifically the half to as Kettering agenT-XXX Agenus, Dr. there cell Agenus X the funded therapies. is are often engraftment top capability patients with quarter. second-line therapy of we unmet Memorial collaborators externally cell in remains improve this cells respiratory finally, chemotherapy, of distress. our botensilimab balstilimab, in approved Cancer Oncology transplantation. that virally GvHD undergoing anti-CTLA-X patients, care from in the with T natural Janjigian, to Gastrointestinal standard Phase by an success will is First, clinical binds optimized respiratory also and GvHD. and hematopoietic the on of distress from multifunctional acute trial advancing in well disease no track at complication demonstrated cells of will be reported also of and need top to of currently GvHD. survival than technology data and led more in This our induced Yelena not but as on in launch This an is where opportunistic include state anti-PD-X care These a these engaging infectious of combination trial cancer, autoimmunity, patients Sloan to an combination on on well.Next, at and

we are this opportunistic support advancing tolerability indication effective We need. available. address externally robust trial pathways unmet small trial that rapid data external and where believe our to are important and Given to this generate data, funded can development

parallel the year.In capabilities this hear our our to we will later our cell to You continuing on these all scale GOP X of and ensure advancing and earlier. therapeutic other manufacturing that We're I can is clinical meet production, more as of continuing to being needs patients cancer diseases. iNKT endeavors, programs team mentioned immune-related our

generation, advanced data Our platform. our we've judiciously with progress scalability prudence, effective emphasized and allocated advanced is resources, financial innovative

innovation will continue are call ways Our the operational balance efficiency.Additionally, to focused the leveraged underscores core internalization existing our on collaboration our go Christine partnerships, infrastructure discussions our services, development on effectively.I to partners fees, been which fullest, development over cost rapidly to in now our to accelerating advancing and financials. its our and commitment strengthen and allowing process, which to research business our nondilutive over full leveraging our we're for fund and to manufacturing of in manufacturing sheet, turn to with our has strategic capabilities regional of effectiveness all more

Christine Klaskin

million cash December compared $XX as We Jen share months reflecting decrease period is call X in to September balance million that XX, just $X.XX turn XXXX for September Thank the for loss $X.XX $XX.X XXXX, compared of the XX, ended at of million per $X.X same XXXX, a $X.X for million period compared and XX, the you, financial and with same XXXX. XXXX, for used for prudence or June the our and the back was to million operator X in Jen. the million, or XX, million described.Net loss million per X questions. to at XXXX, $XX.X when and share.I Cash $XX.X will a net million third ended to in This months was the $XX.X $XX.X respectively. operations ended now quarter $X.X

Operator

for your open Bodnar Wainwright. question The floor first now from is Your [Operator Emily H.C. Instructions] from questions. comes

Emily Bodnar

what X median Maybe in can therapies month algo you SITC, persistence. you of firstly, And if in the the ] into also you persistence some discuss you X you PFS cell those that of setting. the can had Maybe put typical a presented context I about data our combination. talked know in [ is at months

what a So maybe what population. of expect PFS use you similar inhibitors would the just patient checkpoint to be, discuss alone in

Jennifer Buell

population. going And is compelling. that with prior lines pembro. had had overview Their imagine, me. who for typical therapy, chemo, respect with setting less that, Marc SITC. really cervical at in type. with course, we've who the you failed been on as median setting has cell you which, all X presented far non-small of failed a had they the median [ lines you sick. refractory an depending on to I X It's to This of in is a currently population. of I have lines testicular prior can have give quite therapy PFS, were population of X exceeded really closer data And prior lung patients, than I'm who failed with patients X of would disease out, the patient X.X would translational to tumor cancer particular cancer, to Phase their prior cancer, him pointed months, this PFS, therapy We quite available We had cases, in some this observed have therapy and say the heterogeneous the ] as about

that for we a hear to we over from glitch the overall may a you over technical cell to expect, now give seen product. think the what what are progression-free data data, through we're framing, have Marc we of sense patients reference follow would turn disease-free believe for translational you him, as this Marc? in and types may we've just development seen So we've gone of Can of it time, seeing as what I Emily? what Marc. mean continuing well have to I'll the survival the comparative as and we little we survival.The for

Emily Bodnar

I hear you. No, just

Operator

I is unmuted. think now Marc

Marcus van Dijk

Is better? this

Jennifer Buell

Perfect. Yes.

on. You're

Marcus van Dijk

Okay. Good. way to Yes, answering I my was question. on already well the

in patients been T setting the any do haven't reported the a lymphodepletion that patients' And full immune have preconditioning they new heavy to away. on received by setting this, persistence autologous pretreated that I the on, they toxic heavily autologous anywhere cells. cells the in, patients In allogeneic cells that trials, and haven't T extends with from any T have see are that's in So I've the we detected preconditioning reported a non-HLA for match. than And for which in yet. cases, and decades, like persistence spike therapy also of fact HLA room down other seen And own system CAR-T matched with I that's itself, longer make month. lymphodepletion HLA patient and any the seen the are cell seen that coming X-month those a don't but We or tone quite an way. patients without is persistence that. allogeneic In is cells then T full cases, go matched some pediatric to that

have have we still see any that we And we cell else reported anyone other X-month HLA persistence. match, in pretreatment setting. haven't So the type I no no and and or seen

and cells. So that's fairly property of unique we what think, iNKT special think these we a

Emily Bodnar

iNKT the CAR could if Very your clinic? cell you those on update just helpful. an then And if you're provide maybe still advancing for and therapies

Jennifer Buell

I we've best-in-class been this Emily, second who great next-generation we both see MiNK. FAP-CAR-iNKT mentioned as our question. We preclinically, partnerships in that shown calls, actively packet. broader have our absolutely we are. contemplated got with BCMA a completed which and we've and and program this the have ID-enabling BCMA-CAR-iNKT activity in forward, armored, opportunistic companies the as potential with of We've as effectively highlighted programs we've prior for BCMA-CAR-iNKT than have our advancing a with therapy deep discussions is that something developing footprint are the

FAP-CAR-iNKT that was Marc I'll to continues this of the advancing. be have preclinical recently is program. of updated something key highlight and some presented year, that that The So data most features

submission. We're our of We track planning XXXX are on our still IND.

Marcus van Dijk

Yes.

to mean, tumors, solid a that we to is tumor that the that We native very think about the impact help has immunosuppressive It's that's we shown of system potentiates the it actually what whole going hope actually quite really of FAP-CAR-iNKT attacking have very, in as because on data. both that, stroma. immune more our by of fundamental that resistant reported in we year extend Just to do seen in data microenvironment the to with mechanisms we're as and iNKT cells. And see of on suppression native cold go we've iNKT publish highly change the sort I FAP-CAR-iNKTs one it vitro well the conferences benefit. excited even that the that for specifically pretty vivo program actually from really tumor on cancer. tumor in hot. is tackle And couple And the to soon. we've in this to that's this systems well a microenvironment reach cells think

for ahead speed full for So us. program this

Operator

next question Jack from from comes Your Baird. Allen

Jack Allen

in on bit a the translational program? the persistence. on more Marc, Congratulations elaborate little quarter. throughout one the about as a my what data it the the on these to data. expansion cells made XXX But first progress could you Maybe and the acute of spoke from you bit the you're dosing translational seeing relates

Marcus van Dijk

Yes.

good a question. that's So

bolus. but one systemic the dosing, billion effect a rare activation is immune we that cell the time why you the the white immune So is And XX% is quite infuse about whole XX% is of of the of reasons system. in which think normal at a see to on what the cells, infusion of time we these blood, of at X we they total your which cells typically, moment get blood are count, when infuse we

blood Beyond that, cells months. we to is for these over see continue detected in X what that be

have which liver, evidence from clinical part data. marrow. that Preclinically, go they the don't we definite of bone lung, Now to they go tissues

remains expect and we in things. actively we and dividing; say how mean And see. currently themselves, in the would division actually not matched. can't detection although be expect of distinguish they're driven given compartments much that over able they're So the but by be actually months case, to relatively that in stay X, and see blood this we is between cells. And active them we X The around that do One, cycling. tumors the stable, We between body. responding of had for patients of evidence sort expansion that cycling X, thought they would can't we much in iNKT longer those go do X also stay of some they're the level to patients, may currently a trafficking the than we around they HLA to

Jack Allen

Got what about you are elaborate call to it. made you're these Great. How kind that of indication-specific relates And as about path some partnership on the product-specific? partnerships forward? a discussions. you bit or it then thinking contemplating? little more comments be you Would Can moving

Jennifer Buell

discovery also company important have together but So, maybe were it's at successful speed the prolific as just such only and capability, partnerships at expand an This establishing Agenus, development parent both I engine incredibly roles strategy. shared leadership Jen. of Marc mind, agenT. of our not is and our that And where and we our part in

and targets, and MiNK have speak engagers, at appetite TCRs, So take all those for engineering our with unique the team his engineer little in-house. items. us for engine, into very fully interested discovery team to targets discovery in Marc underway. be bit In make very I'm CARs, for producing then about to at to And to particularly capability prolific isolate a on order able actively Marc able only time in for incredibly quite but to are for activities with and not are innovation to with of is going leverage our this them that discussions need capability discovery a be our them we novel companies large are that here iNKTs and some active who who

a types of through discovery regard. talking So in that could engine research partner those one development we're and are we collaboration. be would help supporting And of the discussions about to the partners

for that In chemotherapies us expanding immune cells in used that addition, can most seen course, we've benefit, our incredibly and clinic the like optimal as the as combination, to data exploit own has used that anti-PD-X, these and take powerful the in be and hands KEYTRUDA, XXX, of clinical in been with date, to and OPDIVO. an is this combinations therapies well widely opportunity commonly fully generated benefit,

to with addition well novel can demonstrated that, what In clinic as engagers we've benefit technologies. of some cells that observe other the we the preclinically these in expand as more

through that of strategic a the being be enable on of supporting financed. time. not with research support to pursued from actively as where as the So also clinical our optimal to the some both certainly, cells like underway. us will clinic care bringing in these our top for are the discussions to speed in are of those of for There benefit second-line chemotherapy the standard collaborators help expanded and and discussions will are optimal through I've Trials chasing the trial, leveraging global actively we footprint partnership cancer. in Agenus, on that and world.So combinations patients access expand gastric leverage earlier really are acceleration world balstilimab iNKT collaborations footprint to will regional capabilities that of the development cancer start, cancer, of MiNK data standard as and the the mentioned as course, well does at combination the being And able botensilimab us be to randomized to this benefit externally these products, XXX to Janjigian be technologies And in our the have clinic development our to XXX parts plus also expand care cells would call, contemplating in would patients with with in soonest discussions as some of the chemotherapy top the study, parts that the of provide then exciting in are more regionally different capabilities, really from the of through run a during those and cells and experts Yelena and leveraging rapidly well combinations.

Jack Allen

it. Got Great. if a more. I And couple just may,

On the autoimmune see diseases, that as slide it's on it to to the pipeline. great relates the here

[ see program the read here? it its just your and we in added your PRAME that you mentioned I thoughts study As solid relates around a hear it to to should pipeline. that IND then discovery X early expect slide, a initiation, I'd you've innovative Phase XXXX ] potentially I as PRAME multiple the months target potential the have in to the aspect tumors? And programs, of across coming any briefly, love

Jennifer Buell

Excellent.

something effectively On host first launch to question, is acute study a we with at to IND advancing that's versus cell clinic that to new which with clinical getting That the clinic this is disease. plan respect very program the close amending iNKT year in the program, patients graft our into time. the with into XXX this with

we words so, so. do TCR, With we're So to on certainly Marc year, PRAME we'll announcing do a that. to about the be this planning I'll few track to we're say respect prime have believe that

Marcus van Dijk

pretty a because program a working TCRs that's Look, Yes. we've for on long actually now. us been for actually exciting time quite

the the a believe, already including tumor this. will benefit a actually very we to and to you T given sort we into that the to we're do tumors with getting properties T this PRAME. generated, that's one has of and will difficult as FAP-CAR programs the we're exemplify. TCR enhancing it's iNKT quite started in both cells stage, suppressive be PRAME, X them also believe of And well in beyond cell what to we IND. useful both TCR, then cells, to what what TCR solid in and now will and as currently in about with But could of we potential cells show speeding them progress tumor that.And invariant extend the these as the And some good iNKT probably And PRAME. program is has this specific iNKT hoping benefit even know, the preclinical the and currently, they're We that very, the of really with microenvironment. microenvironments And clinical for places approach are express cells have an tumor, following good thing from a or excited they're PRAME TCR PRAME of is several active actually TCRs, extend

So that's, TCR specifically, then program I think, And unique iNKT us. combining a program with aspect cells. expression is of PRAME valuable as the I for very a frontrunner, the think, a

Operator

comes next Mayank Mamtani Your from question B. Riley. from

Brandon Carney

Mayank. Carney Brandon is This on for

another ADCs. on presentation And ADC cells the think TIGIT how just cancer. and sit a Just I there in TIGIT, regarding gastric on think We Janjigian was given first, saw the wondering landscape landscape in gastric. Tuesday, I you emerging was guess, Dr. the that give I presentation on and was in the and think I

Jennifer Buell

Absolutely.

in benefit significant have setting there's [indiscernible] activity what's which attack currently And for and that treated to and like discussed second-line we that at with both of CRC, the disease And of can addition relatively bone, see sites, on GI right are familiar I'm able metastatic to products rapid this setting the opportunistic. patients now also cancers to that way botensilimab that, actually with expand in So endometrial, broadly XXX presentation, peritoneum very we a after the in sites and the lesions active, a to and being but need by being cancer, liver. CRC now, but metastatic only largely therapies in other and is lung available see, seen and is quite not at in in patients ovarian, as urgent patients available patients observations outside we've disease believe escaped the the have And this over in you the overall in with the balstilimab, we failure. also based quite Yelena. in more

agents and currently which top combination the rapid the here the the chemo, immensely best-in-class tolerably with ADC data we but cancer.In as quite potentially what's with believe, believe technology. a Given benefit for combined only the some that quite we've well the cells on approach do preponderance to others and of observations, as evidence that, expanded cells a potential benefit expand observations with will observations of patients patients had and in is cells also to beneficial with addition be we've really seen other that and from combination, us with available, engagers gastric that quite chemo effectively of not top preclinical and bot/bal for those cells from also we could on include path

I So Marc these when cells, what's when have we administer I'll immunologically about we few happening cells. look words that think and a specifically at these say

these FITC presented other observations expansion that insights expanding that only without dose. the cells, are of earlier, therefore, And we you benefit no in at we're modulate the some X regard. And administering see the place observations additional tumor little to with expansion today of a escape developing like technologies. just of mechanisms And Marc give in per see tumor see engagers, these toxic that preconditioning, ways matching, well benefit today of to novel mentioned bit I do our cells on as we not the are without more I tolerable that with with lymphodepletion, technologies eliminate HLA we to we as with microenvironment approved. these approved over which that billion also not of technologies So from now therapies yet observe appear cells cells the in some a

Marcus van Dijk

And on cells. to, lot for And one unique instance, CDXd, we've And is myeloid in due IO suppressor MX that, of part macrophages MX actually I think tumor a at within a mean, of universally target modulate and their see through that myelo-derived kill least the iNKT or today, And we they they for part, we instance. of also seen big Yes. is resistance of macrophages which specifically, invariant large microenvironment. the are the all that think, cells, can failures is TCR, cells. I cells myeloid features macrophages that expressed

possible with they way start ] is we [ potentially what a checkpoints. beyond microenvironment really much that positive think a can tumor. changing effect together And immune the additive an that's that better in with So checkpoints,

the that it don't why system. is of clinical cells because standard that possible operates these immune And care instance, lymphodepletion. that we patients the in or we the augment gastric without cells or in way think of, on we for sort changes that's the to tumor fact think helps itself. top iNKT immunosuppressive also, the know of really the bot/bal mechanisms tumor We overall of attack address starts nonoverlapping chemo So to cancer response their course,

also the quite achieve do overall If We patients, their of effect the we we significantly. checkpoints actually you you because do diminishes don't with, cells don't iNKT diminish setting. We system infusion conjunction in given it, for we a but can because lymphodeplete of immune don't that that need think don't do that. on instance, it clinical what

all that much additive at question? a great Does we there So key iNKT think your reason that's to cells pretty therapies the the out answer the moment. IO are why

Brandon Carney

the that forward? and now Yes, there responses critical guess going just we if to to and see that's you yes. that there's an helpful. what give you mentioned I'm that just on No, think wondering follow between levels of trend trend maybe update to confidence in right can up you I expect XXX. And from

Marcus van Dijk

we You that to light to is if redose or persistence, we to why help surprises in key read this follow makes us. those. we This and decide because, to and for quite do sense actively patients, what when how for us instance. would it it mean us redose to when data continue should thinking yes, be And about redose also honest, our actually to in of the on

why and lot disease that we'll in just that on more detect of iNKT how be the and patients we of to are responses also collecting this either phenomenon because persistence is data And patients So try happening. a we what's indications early stable we response. cells have that or to understand some relates have higher in it levels partial

Brandon Carney

dropped I Got out. it. the patient lastly, I that And to testicular wanted ask then guess on

patient Just also, that SITC give behind you the that? the us presented other testicular us at on cancer And give wondering poster update details I Can there's any mentioned on if could testicular. expansion for think any And details AACR. any that? that you the was an reasoning cohort if on

Jennifer Buell

Absolutely.

who come single follow the a testicular order right at but administering those that we to observations also continue have that patients currently to current given we we administration even trial are that biologically actually the choices continue choice, time more the made the refractory and the patient trial early, necessarily some family in And who the now in to everyone patient would [ There's seen in here biopsy in get is collect. the them. information with disease for patients. the spend and as somewhat available part we're from what with patients samples samples enough now to is are And cancer. as survival the we're from nothing well clinic. follow we off continuing of And So for compelling. they've see And not to the just looking that if in quite we've durable this continuing trial, stabilization peripheral ] paired cells now in really

So that the of us just to discontinue did available and study follow-up period us. to still patient accessible the who is

continued a really stabilization, The other patient durable disease quite intriguing. and it's is

our So hands. expand we will in trial the own

it very seen a our are relapsed/refractory Phase who areas therapies. cancer. some testicular X to cell other lung cancer, Our includes disease And have that some responsive where Xb, not in Phase and understanding deepening patients going we and in addingan additional signals non-small gastric, patients into dose includes specifying it activity some to includes of trial provocative specific

of to meetings, be course. data and will at those continue updates so over develop And sharing upcoming we'll time,

Operator

question Phipps next comes William Blair. Matt Your from from

Matthew Phipps

effect you to gastric specifically the reason just there's Given outsized patient, any that think MSI cancer do in cancers? high at look

Jennifer Buell

very we've well respect I'll first, have for group, MSS. the as MSI as Well, observations highlight a high Marc, a the that's broader couple maybe More with seen to intriguing that just question. of broadly,

as particularly germline biologic microsatellite our our are have well expanding pathologic to seeing or point, [ continued some of patients combinations, as stable seen Some activity. tumors observations of some rationale in Matt, stable, but using more high, given evidence way, ] we're some in the your the observations we Maybe a a agnostic MSI but there broadly Marc... where about of may be

Marcus van Dijk

Yes.

expect is So interesting because MSI new could high type more there's an tumor you epitopes there.

So there's more one it's the in of existing indications intrinsic pembrolizumab sort patients. T where of response. T the priming capitalizes on which is the approved, cell And cell

was this on was progressing pembro. patient are But tumors those not on particular progressing entirely So nivo cold.

clearly, the microenvironment to though was that tumor enough. T was still we not resistance cancer, So cells iNKT this full in specific some prior tumor There with treatment in neoantigen-specific that prevented cells. even the detected response his so

in So the iNKT prevented that he or we expand in because state. the progressing added appears cells it was of blockage diminished the even that cells, removed to was that starting to T T were some the cells tumor dramatically. When activate

that reduce an blocked. existing able happening of a So a iNKT tumor that way to T some we local in lot me that's don't potentiate response, more already in T think was of cells further suppression the but cell the see iNKT is of speaks in tumor to microenvironment to what CDX And cells post is infusion are sort cells. the we that

that led is clearly And think you example cancer change existing particular if block gastric tumors? patient reducing activation then So it course, iNKT of in the the there.Do by still mechanism and T IO additional this indicates I see iNKT T cancer PD-X by that's not in is think that of a response? cell there cells an that, in we is also other have cell is with many earlier that we cases, we standard best to what tackled then benefit and helps Well, further is possible. of And potentially response, this gastric can I have patient alluded that the having suppression pretreated overlapping and of enough. And progressing state probably has a to been cells. therapies. not

that. to So see we of more hope

Matthew Phipps

Sorry to redosing if how seen? I said guys missed you frequently you've given or it, the multi-dosing persistence test but you're have going

Jennifer Buell

what give to I'll on Again, insight currently. this. could ask we're Marc, I some you you thinking tell

at us where for important peripherally, as are clinical most based the does probably the is and Our continue the thinking administration we dose, X this to the us cells weeks. dose any and time is persistence could a need we sense component now team locally trafficking the the don't tumor. separate that right of site is give to than at localizing, less we on the out

care some the can on we within we fact [indiscernible] presented that, the to in antibodies, that us And who which at based wandering time, But believe may, push seen current could more an that of the pronounced answer based time. appears weeks? out, possibly enables benefit. this be already weeks on And on may change patients mark, that we still of explore SITC trial. and around don't that rejection. us the dose will we persistence microenvironment point optimize at transient the any tumor types And expansion optimize years spot ago, something to gives combine the safely patients a localization? for delaying we've X and and tumor widely without have to that it where deeply therapies X undergoing the established dose sweet that which know used should favorably Does we our be of we we the in convenience the the at to XX going to in in seeing care. it that explore time dynamics doing So to is this that we very in standard benefit the are this really we're which the cohorts, our we we're the standard most with particularly X-week well at we're opportunity And the

Operator

That Buell final was now closing for over remarks. question. our it I to turn Dr.

Jennifer Buell

continued to appreciate all thank support much, time. you very MiNK. your for and and I you operator, and Thank time attention your

MiNK Therapeutics (INKT) 9 Nov 232023 Q3 Earnings call transcript